Pharming signs agreement with NewBridge Pharmaceuticals for the commercialization of RUCONEST® in the Middle East and North Africa
USA - English
Share this article
Share this article
LEIDEN, Netherlands, July 20, 2021 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM) (Nasdaq: PHAR) announces it has entered into an exclusive licence agreement with NewBridge Pharmaceuticals ("NewBridge") for the distribution of RUCONEST® (conestat alfa) in the Middle East and North Africa ("MENA").
NewBridge, headquartered in Dubai, United Arab Emirates, is a regional specialty company, with a comprehensive pharmaceutical platform of services and expertise, established to bridge the access gap and partner with global pharma and biotech companies to in-license and commercialize US Food and Drug Administration (FDA) or European Medicines Agency (EMA) approved innovative therapeutics that address unmet medical needs into MENA.